Coya Therapeutics, Inc.’s Post

Pathogenic IgA in MS

IgA in neurology beyond Alzheimer Disease Direct proof that there are systemic autoantibodies of the IgA isotype against myelin basic protein in a patient suffering from Multiple Sclerosis by the group of Prof. Harald Pruss. With CD89-expressing peripheral neutrophils and monocytes that can enter the brain through branches of the BBB at the lesions and CD89 microglia cells as resident immune cells in the CNS, these IgA deposits on MBP will result in activation of these immune cells. The effector functions of these CD89 bearing immune cells cause pathogenic inflammation and damage. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

Exploring Allogenic CD19-Targeted CAR-T Therapy for Autoimmune Conditions: A Breakthrough Response Three patients with autoimmune diseases have shown positive responses to allogeneic CAR-T therapy, marking a significant first for the “off-the-shelf” cell therapy technology. Furthermore, this research, conducted in China and published in Cell on July 15, provides the novel evidence directed at the potential of this allogeneic CAR-T therapies in specifically treating autoimmune diseases. https://lnkd.in/gMf5Rjkk

Sage Therapeutics has decided to stop the development of dalzanemdor (SAGE-718) for Alzheimer’s disease. The Phase 2 LIGHTWAVE trial showed the treatment was safe and well-tolerated but did not significantly improve cognitive function compared to placebo. Dalzanemdor aimed to enhance NMDA receptor activity, which is critical for nerve cell communication and memory formation. In Alzheimer’s, impaired NMDA receptor signaling is believed to contribute to cognitive decline, making it a potential target for therapies seeking to restore brain function. Sage’s CEO expressed gratitude to the participants and the Alzheimer’s community for advancing this important research. Further reading: [Sage Therapeutics News Release] (https://lnkd.in/gzfssRuu) #Alzheimers #Research #ClinicalTrials #Syrentis

#podcast Alon Ben-Noon, CEO and board member of NeuroSense Therapeutics, is taking a unique approach to treating neurodegenerative diseases by targeting core pathologies and combining molecules to address various mechanisms. NeuroSense has seen positive clinical trial results for ALS using their lead compound PrimeC, which showed a reduction in disease progression. Research indicates the potential for this approach to be applied to other neurodegenerative diseases like Alzheimer's and Parkinson's.   #NeuroSense #ALS #Parkinsons #Alzheimers #NeurodegenerativeDiseases NeuroSense-TX.com https://lnkd.in/g2FhVhDK

🎥 Exciting Advancements in MASH Research! 🌟 Explore the latest in metabolic dysfunction research using Cyagen's Composite Mouse Models. These models provide invaluable insights into obesity, diabetes, and liver conditions such as inflammation, fibrosis, and cancer. Discover how they aid in preclinical drug development, showcasing the positive effects of treatments like Rasum. Learn more about our models and collaboration opportunities. Let's advance liver disease research together! 🧬 #MASHresearch #biotech #liverdisease #Cyagen #researchinnovation #biotechnology #biosciences #researchimpact

Are you exploring options for in vivo testing of small-molecule GLP-1R agonists? Our new humanized GLP-1R mouse model is developed specifically for preclinical obesity research. Tailored for translational insights, it offers a reliable platform for advancing your studies. Flip through the slides or visit our website to learn more: https://lnkd.in/dWKEQTC5 For any questions, connect with Marco Tozzi and Kristopher Abney.   #GLP1R #ObesityResearch #CROservices

🧠 Could targeting mitophagy transform neurodegenerative disease treatment? A new article in Nature Reviews Drug Discovery explores how enhancing mitophagy — the process of clearing damaged mitochondria — could address mitochondrial dysfunction, a hallmark of neurodegenerative diseases like Parkinson’s, ALS, Alzheimer’s, and Huntington’s. With promising preclinical evidence, small-molecule approaches such as USP30 inhibitors and PINK1 activators are now advancing to phase I clinical trials, offering hope for neuroprotection and disease modification. 📖 Read more: https://lnkd.in/dePNRF7h #WorldMitochondriaSociety #WMS #TargetingMitochondria #Mitophagy #NeurodegenerativeDiseases #MitochondrialHealth #ParkinsonsDisease #ALS #AlzheimersDisease #HuntingtonsDisease #DrugDiscovery #Neuroprotection #TranslationalResearch #ClinicalTrials

Exosome-based biomarkers could play an important role in the treatment and diagnosis of neurodegenerative diseases such as ALS, Alzheimers and Parkinsons. We have just entered into a collaboration with NeuroSense Therapeutics to identify exosome-based biomarkers, to advance neurodegenerative disease treatments and diagnostics. We will develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes (“NDEs”), set to be integrated into the clinical development program of PrimeC, NeuroSense's lead drug candidate. NDEs are small extracellular vesicles generated by neurons that encapsulate a variety of molecules. Identification and measurement of NDEs and their cargo can facilitate the discovery of new biomarkers for prognosis and therapy, as these vesicles can pass the blood-brain barrier and noninvasively provide a depiction of the current physiological status of neurons in the brain. Read more about the agreement here: https://lnkd.in/dt8H8Vnv If you want to find out more about exosomes, as well as their potential therapeutic applications, take a look at our infographic ⬇   #AHealthierWorld #Collaboration #Innovation #CellTherapy #Exosomes